Find out what drove John McKearn, Ph.D. & CEO at Wugen, out of the lab at Pfizer and on to his quest to develop off-the-shelf cell therapies for T-Cell leukemias and lymphomas, Acute Myeloid Leukemia, and Multiple Myeloma.
Not yet a member of BioProcess Online? Register today.
Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.
You might also want to: